Download Report Global GABA Receptor Agonist Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024

“Global GABA Receptor Agonist Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024” Report Highlights:

* Global GABA Drugs Market Analysis by Dosage and Price
* Promising GABA Receptor Agonist Therapeutics
* Trends and Market Dynamics of GABA Receptor Agonist
* Global GABA Receptor Agonists Clinical Pipeline = 49 Drugs
* Marketed Global GABA Receptor Agonists Clinical Insight = 28 Drugs
* GABA Receptor Agonist Market Analysis by Indication

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-gaba-receptor-agonist-drug-market,-dosage,-price-and-clinical-pipeline-outlook-2024.php

Table of Contents

1. Prologue to (Gamma Amino Butyric Acid) GABA
1.1 Gamma - Amino Butyric Acid (GABA) andndash; Chief Inhibitory Neurotransmitter of the Central Nervous System
1.2 GABA Receptors and Their Importance
1.3 GABA Receptor - Role and it’s Working Mechanism

2. Major Classes of GABA Receptor Therapeutics
2.1 GABA Receptor Agonist (Activators)
2.2 GABA Receptor Antagonist (Inhibitors)

3. GABA Receptor Market Segmentation by Type
3.1 GABAA
3.2 GABAB

4. Global GABA Drugs Market Analysis by Dosage and Price
4.1 Gabapentin (Gralise, Neurontin, Gabarone, Fanatrex)
4.1.1 Horizant (Gabapentin Enacarbil)
4.1.2 Regnite (Gabapentin Enacarbil,Japan)
4.1.3 Solzira (Gabapentin Enacbril)
4.1.4 Gralise (Gabapentin Enacbril)
4.2 Zolpidem
4.2.1 Ambien and Ambien CR ( Zolpidem Tartrate)
4.2.2 Edluar
4.2.3 Intermezzo
4.2.1 Zolpimist
4.3 Other Marketed GABA Receptor Therapeutics andndash; Dosage and Price Analysis
4.3.1 Diastat AcuDial (Diazepam)
4.3.2 Campral EC (Acamprosate)
4.3.3 Stiripentol (Diacomit)
4.3.4 Gamibetal (GABOB)
4.3.5 Loreclezole
4.3.6 Lunesta(Eszopiclone)
4.3.7 Piacmilon
4.3.8 Onfi(Clobazam)
4.3.9 Gabrene (Progabide)
4.3.10 Diprivan (Propofol)
4.3.11 Regtect
4.3.12 Sonata Oral (Zaleplon, Starnoc, Andate)
4.3.13 Topamax Migraine

5. Promising GABA Receptor Agonist Therapeutics
5.1 Bamaluzole
5.2 Phenibut
5.3 Baclofen
5.4 Gaboxadol
5.5 Klonopin (clonazepam)
5.6 Tiagbine
5.7 GABA as Food Supplement

6. Global - Trends and Market Dynamics of GABA Receptor Agonist
6.1 Entry of Promising Therapeutics into the GABA Market Segment
6.2 Increasing Opportunities in Psychological Disorders Market

7. GABA Receptor Agonist Market Analysis by Indication
7.1 Attention Deficit Hyperactivity Disorder (ADHD)
7.2 Psychiatric Disorders and Depression
7.3 Alzheimer
7.4 Epilepsy and Seizure
7.5 Anxiety and Sleep Disorders
7.6 Obesity and Alcoholism

8. GABA Receptor Market Analysis by Region
8.1 US
8.2 Europe
8.3 Asia Pacific
8.4 Rest of the World

9. GABA Receptor Agonist Market Driving Parameters
9.1 Increasing Prevalence of GABA Related Disorders
9.2 Increase in Research and Development
9.3 Presence of Robust Clinical Pipeline

10. GABA Receptor Agonist Market Challenges
10.1 Scientific and Technical Limitations
10.2 Limited Research in GABA Therapeutics Segment and Cost Factor
10.3 Lack of Awareness and Low Market Penetration of GABA Receptor Agonist
10.4 Unregulated Market and Stringent FDA Regulations

11. Global GABA Receptor Agonist Market Future Forecast

12. Global GABA Receptor Agonists Clinical Pipeline by Company, Indication and Phase
12.1 Global GABA Receptor Agonists Pipeline Overview
12.2 Unknown
12.3 Research
12.4 Preclinical
12.5 Clinical
12.6 Phase-I
12.7 Phase-II
12.8 Phase-III
12.9 Preregistration

13. Marketed GABA Receptor Agonists Clinical Insight by Company and Indication

14. Competitive Analysis
14.1 Advicenne
14.2 AstraZeneca
14.3 Athena Drug Delivery Solutions
14.4 Biocodex
14.5 Elan Corporation
14.6 Eli Lilly and Company
14.7 H.LundBeck, Merck and Co
14.8 GlaxoSmithKline
14.9 NovaDel Pharma
14.10 Novartis
14.11 OVATION Pharmaceuticals
14.12 Osmotica Pharmaceutical
14.13 Pfizer
14.14 sanofi-aventis
14.15 VIVUS
14.16 XenoPort

Figure 1-1: GABA - Most Abundant Neurotransmitter
Figure 1-2: Features of GABA Receptors
Figure 1-3: GABA Receptor Activation and Function
Figure 2-1: Potential Therapeutic Role of GABA
Figure 3-1: Structure of GABAA
Figure 4-1: Gabapentin (Neurontin) - Dosage Analysis (mg)
Figure 4-2: Gabapentin (Neurontin) - Price Analysis (US$), 2018
Figure 4-3: Horizant - Dosage Analysis by Indication (mg/day)
Figure 4-4: Horizant- Price Analysis for 300mg and 600mg Pack(US$), 2018
Figure 4-5: Regnite - Price Analysis by Region (US$), 2018
Figure 4-6: Ambien - Maximum Permissible Dosage by Gender (mg)
Figure 4-7: Price Analysis -Ambien CR Oral Tablet (US$/30 Tablet Pack), 2018
Figure 4-8: Intermezzo - Dosage Analysis (mg)
Figure 4-9: Zolpidem - Price Analysis by Product, 2018
Figure 4-10: Diazepam Rectal Gel - Dosage Analysis by Age (mg/kg)
Figure 4-11: Diazepalm - Price Analysis by Product, 2018
Figure 4-12: Dosage Analysis - Acamprosate Tablets per day by Weight
Figure 4-13: GABOB- Maximum Recommended Dosage in Children by Condition (mg/Day)
Figure 4-14: GABOB - Maximum Recommended Dosage in Adults by Condition (mg/Day)
Figure 4-15: Propofol- Price Analysis (US$/ml), 2018
Figure 4-16: Global - Propofol Sales Analysis (US$ Million), 2013
Figure 4-17: Sonata Oral - Price Analysis (US$), 2018
Figure 4-18: Topomax - Monotherapy Dosage Analysis for patients andgt;10 years (mg)
Figure 4-19: Topamax - Monotherapy Dosage (mg) Analysis for Patients andlt; 10 years by Weight (kg)
Figure 4-20: Topamax - Price Analysis for 15 Tablet pack (mg), 2018
Figure 5-1: Global - Propofol Sales Forecast (US$ Billion), 2015-2024
Figure 5-2: Baclofen - Price Analysis (US$/mg), 2018
Figure 5-3: Baclofen - Intrathecal Solution Price Analysis (US$/ml), 2018
Figure 5-4: Global - Baclofen Sales Estimates (US$ Million), 2015 -2024
Figure 5-5: Tiagbine - Dosage Analysis by Indication (mg)
Figure 7-1: GABA Market Segmentation by Indication
Figure 7-2: Global - ADHD Prevalence by Region (%), 2016
Figure 7-3: Global - Prevalence of GABA Related Disorders (%), 2017
Figure 7-4: Global - Alzheimer Prevalence Forecast (Million) 2016-2050
Figure 7-5: Global- Number of Patients Diagnosed by Epilepsy (Million), 2016
Figure 7-6: Sleep Disorders Prevalence by Region (%), 2016
Figure 7-7: Global - Estimated Annual Cost of Sleep Disorder (US$ Million), 2016
Figure 8-1: US- ADHD Prevalence by Age (%), 2018
Figure 8-2: US-ADHD Prevalence by Gender (%), 2018
Figure 8-3: US- ADHD Prevalence by Race (%), 2018
Figure 8-4: US andndash;People Diagnosed with GABA Related Disorders (Million), 2012-2016
Figure 8-5: Europe - Alzheimer’s Prevalence by Age (%), 2014-2016
Figure 8-6: Asia - Prevalence of ADHD among Children by Region (%), 2012-2016
Figure 8-7: Asia Pacific andndash; GABA Related Sleep Disorder Prevalence (%), 2015-2016
Figure 9-1: Driving Factors of GABA Agonist Market
Figure 9-2: Current Psychiatric Drug Pipeline, 2018
Figure 10-1:GABA Receptor Agonist Market Challenges
Figure 12-1: Global - GABA Receptor Agonists Clinical Pipeline (%), 2018 till 2024
Figure 12-2: Global - GABA Receptor Agonists Clinical Pipeline (Number), 2018 till 2024
Figure 12-3: Global - GABA Receptor Agonists Clinical Pipeline (%),2018 till 2024
Figure 12-4: Global - GABA Receptor Agonists Clinical Pipeline (Number), 2018 till 2024

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.